Fundação Butantan
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
1
Ending by 2030
Oct 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 18, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,827,299 | Selectively Disrupted Whole-Cell Vaccine In force · High confidence | In force | High confidence | |
| US 9,512,186 | Recombinant strain of Mycobacterium bovis bacillus calmette-guerin (BCG), immunogenic composition and use In force · From the USPTO record | In force | From the USPTO record | |
| US 11,278,574 | Use of stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease In force · From the USPTO record | In force | From the USPTO record | |
| US 11,306,290 | Stem cells expressing mesenchymal and neuronal markers, compositions thereof, and methods of preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,498,498 | Adipose tissue mesenchymal stem cells and methods of use to treat or inhibit uterine disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 12,480,095 | Multifunctional immature dental pulp stem cells and therapeutic applications In force · From the USPTO record | In force | From the USPTO record | |
| US 12,239,670 | Use of stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease In force · From the USPTO record | In force | From the USPTO record | |
| US 10,081,660 | Polynucleotide, Polypeptide with Immunosuppressive Activity, Expression Cassette, Expression Vector, Host Cell, Pharmaceutical Composition, Methods for Producing a Polypeptide with Immunosuppressive Activity and for Preventing or Treating Conditions That Require Immunosuppression, and Use of a Polypeptide In force · High confidence | In force | High confidence | |
| US 9,833,444 | Use of chemical compounds that can inhibit the toxic activity of sphingomyelinase D from venoms of Loxosceles spiders and pharmaceutical composition comprising said compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 11,207,352 | Compositions comprising stem cells expressing mesenchymal and neuronal markers and uses thereof to treat neurological disease In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 8 no status recorded